Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials
In previous phase I/II oncology trials for drug combinations, a number of methods have been studied to determine the dose combination for the next cohort. However, there is a risk that trial durations will be unfeasibly long if methods for evaluating safety and efficacy are based on the best overall...
Main Authors: | Shinjo Yada, Chikuma Hamada |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | Contemporary Clinical Trials Communications |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865416301314 |
Similar Items
-
Phase 0 clinical trials in oncology new drug development
by: Umesh Chandra Gupta, et al.
Published: (2011-01-01) -
Phase II Trials in Drug Development and Adaptive Trial Design
by: Gail A. Van Norman, MD
Published: (2019-06-01) -
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
by: Lauren A. Marcath, et al.
Published: (2018-11-01) -
A modified estimation of treatment effect using combined information from Phase I and Phase II oncology clinical trials
by: Wei-LingChen, et al.
Published: (2010) -
Phase 0 clinical trials: theoretical and practical implications in oncologic drug development
by: Coloma PM
Published: (2013-10-01)